Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersNCT05626803VaxartPhase 2Completed2023-10-16Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.